Skye Bioscience presenting at GLP-1-Based Therapeutics Summit. SAN DIEGO, April 07, 2026 (GLOBE NEWSWIRE) - Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye") a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will present at the GLP-1-Based Therapeutics Summit in Boston, MA, being held April 14-16. Presentation Details Title: Maximizing Efficacy, Minimizing Risk by Leveraging Peripheral CB1 Antagonism in Combination with GLP-1 Agonists to Advance the Obesity Treatment Paradigm Presenter: Punit Dhillon, President & CEO Date: Thursday, April 16, 2026 Time: 1:30 pm About Nimacimab Nimacimab is a potential first-in-class, peripherally-restricted monoclonal antibody inhibitor of the CB1 receptor. Unlike previous CB1-targeting drugs, nimacimab is designed to avoid central nervous system penetration, potentially limiting neuropsychiatric side effects seen with small-molecule antagonists. As a non-incretin, non-peptide agent, nimacimab acts independently of the GLP-1 pathway and has demonstrated additive effects in combination with semaglutide in the Phase 2a CBeyond trial. The Company is developing nimacimab as a potential orthogonal add-on therapy for patients with obesity who are experienced on or have plateaued with GLP-1-based treatment, targeting clinically meaningful incremental weight loss, improved body composition, and reduced weight regain without added gastrointestinal or neuropsychiatric burden. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov: NCT06577090) in obesity and overweight for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy(R). For more information, please visit: www.skyebioscience.com. Connect with Skye Bioscience Inc. on X and LinkedIn. Investor Relations [email protected] (858) 410-0266 LifeSci Advisors, Mike Moyer [email protected] (617) 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhugh [email protected] (415) 269-7757 FORWARD-LOOKING STATEMENTS This press release includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements relating to: the potential for higher dosing of nimacimab to achieve increased efficacy; the potential for the combination of nimacimab and semaglutide to deepen weight loss and mitigate weight rebound; the potential for future weight loss beyond 52 weeks; plans to advance nimacimab into the next stage of development to optimize dosing; future clinical development of nimacimab, including the initiation and design of any future clinical trials; the expected timing for reporting topline data from the Phase 2a extension study; the ability of nimacimab to drive weight loss without neuropsychiatric and other adverse events; the potential for nimacimab to be a first-in-class drug; the potential for Skye to develop a leading orthogonal platform to intensify incretin outcomes and help patients achieve more durable metabolic benefit; the commercially competitive nature of nimacimab combined with semaglutide; and the potential for nimacimab to be a long term option in obesity and related metabolic diseases. When used herein, words including "anticipate," "believe," "can," "continue," "could," "designed," "estimate," "expect," "forecast," "goal," "intend," "may," "might," "plan," "planning," "possible," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon Skye's current expectations and various assumptions. Skye believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Skye may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important risks and uncertainties, including, without limitation, the initiation and design of any future clinical trials will be impacted by Skye's capital resources, Skye's ability to obtain additional sources of capital needed to run an additional Phase 2 clinical trial, program considerations and potentially other factors outside the Skye's control; the potential for additional weight loss after 52 weeks may not ultimately be observed; there is no guarantee that higher dosing of nimacimab will achieve increased efficacy, and likewise it is possible that higher dosing will produce adversely different safety and tolerability results than those observed to date; Skye's dependence on third parties in connection with product manufacturing; research and preclinical and clinical testing; Skye's ability to advance, obtain regulatory approval of and ultimately commercialize nimacimab, competitive products or approaches limiting the commercial value of nimacimab; the timing and results of preclinical and clinical trials; Skye's ability to fund development activities and achieve development goals; the impact of any global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, adverse regulatory changes; Skye's ability to protect its intellectual property; risks associated with Skye's common stock and the other important factors discussed under the caption "Risk Factors" in Skye's filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024, which are accessible on the SEC's website at www.sec.gov and the Investors section of Skye's website. Any such forward-looking statements represent management's estimates as of the date of this press release. While Skye may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause Skye's views to change. These forward-looking statements should not be relied upon as representing Skye's views as of any date subsequent to the date of this press release. Released April 7, 2026

Skye Bioscience (SKYE) reprices 2.42M options and taps John Sharp as CFO. Filing Impact (Moderate) Filing Sentiment Rhea-AI Filing summary. Skye Bioscience, Inc. approved a broad stock option repricing and appointed a new chief financial officer. Effective March 31, 2026, all eligible employee stock options granted before December 31, 2025 under the company's incentive plans had their exercise prices reset to $0.6150 per share, matching the common stock's closing price that day. This affects 2,420,978 shares in total, including options for the CEO and COO, and is intended to retain and motivate employees without issuing additional equity or cash compensation. On the same date, the board named John P. Sharp as Chief Financial Officer and principal financial and accounting officer. His services are provided through a Master Services Agreement with Lohman & Associates, under which the company pays $25,600 per month for up to 64 hours of CFO and related advisory services. 8-K event classification. 2 items: 5.02, 9.01 Key figures. Repriced option exercise price: $0.6150 per share Total repriced options: 2,420,978 shares CEO repriced options: 1,103,959 options +4 more Key terms. Option Repricing, 2014 Omnibus Plan, Master Services Agreement, Statements of Work, +1 more 04/03/2026 - 04:46 PM | / | / | / | / | / | Faq. What stock option changes did Skye Bioscience (SKYE) approve on March 31, 2026? Skye Bioscience reset the exercise price of certain employee stock options to $0.6150 per share, equal to the common stock's closing price on March 31, 2026. The repricing covers 2,420,978 shares granted before December 31, 2025 under its equity plans. How many Skye Bioscience (SKYE) options for executives were repriced? The repricing includes underwater options held by CEO Punit Dhillon and COO Tuan Diep. Dhillon had 1,103,959 options repriced, while Diep had 396,295 options repriced. Their original exercise prices ranged from $2.89 to $14.56 per share. Who is the new Chief Financial Officer of Skye Bioscience (SKYE)? Skye Bioscience appointed John P. Sharp as Chief Financial Officer and principal financial and accounting officer effective March 31, 2026. He is a veteran finance executive with more than 30 years of experience in biopharmaceutical companies and public accounting roles. How is Skye Bioscience (SKYE) engaging John Sharp as CFO? John Sharp's CFO services are provided through a Master Services Agreement with Lohman & Associates. Under Scope of Work Number One, the firm supplies his CFO time on a fractional basis rather than hiring him directly as a full-time employee of Skye Bioscience. What are Skye Bioscience's (SKYE) CFO service fees under the Master Services Agreement? Lohman & Associates bills Skye Bioscience $25,600 per month for up to 64 hours of John Sharp's CFO services. Any hours above this cap, out-of-scope work, travel or lodging, or rate changes require written approval from both parties. Did Skye Bioscience (SKYE) change other option terms besides the exercise price? The company states that no additional changes were made to the repriced stock options aside from reducing the exercise price to $0.6150 per share. All other terms of the affected options under the incentive plans remain in place. Filing exhibits & attachments. 4 documents Agreements & contracts.